X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs SUN PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA SUN PHARMA ABBOTT INDIA/
SUN PHARMA
 
P/E (TTM) x 40.5 46.4 87.3% View Chart
P/BV x 11.7 3.7 312.8% View Chart
Dividend Yield % 0.5 0.6 85.2%  

Financials

 ABBOTT INDIA   SUN PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-17
SUN PHARMA
Mar-17
ABBOTT INDIA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs5,190842 616.3%   
Low Rs4,351572 760.1%   
Sales per share (Unadj.) Rs1,382.9131.6 1,050.7%  
Earnings per share (Unadj.) Rs130.232.7 398.1%  
Cash flow per share (Unadj.) Rs137.938.0 363.2%  
Dividends per share (Unadj.) Rs40.003.50 1,142.9%  
Dividend yield (eoy) %0.80.5 169.4%  
Book value per share (Unadj.) Rs652.7152.7 427.4%  
Shares outstanding (eoy) m21.252,399.26 0.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.45.4 64.2%   
Avg P/E ratio x36.621.6 169.4%  
P/CF ratio (eoy) x34.618.6 185.7%  
Price / Book Value ratio x7.34.6 157.8%  
Dividend payout %30.710.7 287.1%   
Avg Mkt Cap Rs m101,3731,696,877 6.0%   
No. of employees `0003.117.5 17.6%   
Total wages/salary Rs m3,45349,023 7.0%   
Avg. sales/employee Rs Th9,531.918,028.3 52.9%   
Avg. wages/employee Rs Th1,119.92,798.8 40.0%   
Avg. net profit/employee Rs Th897.34,479.5 20.0%   
INCOME DATA
Net Sales Rs m29,387315,784 9.3%  
Other income Rs m5766,232 9.2%   
Total revenues Rs m29,963322,016 9.3%   
Gross profit Rs m3,973100,893 3.9%  
Depreciation Rs m16412,648 1.3%   
Interest Rs m203,998 0.5%   
Profit before tax Rs m4,36590,479 4.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,59812,116 13.2%   
Profit after tax Rs m2,76778,462 3.5%  
Gross profit margin %13.531.9 42.3%  
Effective tax rate %36.613.4 273.5%   
Net profit margin %9.424.8 37.9%  
BALANCE SHEET DATA
Current assets Rs m18,906329,537 5.7%   
Current liabilities Rs m6,297178,870 3.5%   
Net working cap to sales %42.947.7 89.9%  
Current ratio x3.01.8 163.0%  
Inventory Days Days6279 78.7%  
Debtors Days Days2283 26.0%  
Net fixed assets Rs m1,159204,766 0.6%   
Share capital Rs m2132,399 8.9%   
"Free" reserves Rs m13,657363,997 3.8%   
Net worth Rs m13,869366,397 3.8%   
Long term debt Rs m014,361 0.0%   
Total assets Rs m20,638614,102 3.4%  
Interest coverage x215.023.6 909.7%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.40.5 276.9%   
Return on assets %13.513.4 100.6%  
Return on equity %19.921.4 93.1%  
Return on capital %31.624.8 127.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m044,118 0.0%   
Fx outflow Rs m024,484 0.0%   
Net fx Rs m019,634 0.0%   
CASH FLOW
From Operations Rs m3,07270,822 4.3%  
From Investments Rs m-1,554-42,216 3.7%  
From Financial Activity Rs m-898-22,854 3.9%  
Net Cashflow Rs m6216,107 10.2%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 5.1 154.0%  
FIIs % 0.1 23.0 0.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 8.3 206.0%  
Shareholders   18,270 133,026 13.7%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  DIVIS LABORATORIES  UNICHEM LAB  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)

After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.

Related Views on News

ABBOTT INDIA at All Time High; BSE HEALTHCARE Index Up 0.5%

Jun 25, 2018 | Updated on Jun 25, 2018

ABBOTT INDIA share price has hit an all time high at Rs 7,550 (up 1.60%). The BSE HEALTHCARE Index is up by 0.49%. Among the top gainers in the BSE HEALTHCARE Index today are ABBOTT INDIA (up 1.60%) and SANOFI INDIA (up 0.37%). The top losers include GSK PHARMA (down 0.04%) and JUBILANT LIFE SCIENCES (down 0.13%).

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jun 25, 2018 03:35 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - SANOFI INDIA COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS